title: Landmarks in hormonal therapy for prostate cancer.
abstract: • It is >70 years since the responsiveness of symptomatic metastatic prostate cancer to androgen deprivation was first demonstrated. • Since those pivotal studies, progress in hormonal therapy of prostate cancer has been marked by several important developments and the availability of various androgen-suppressing agents. • Treatment guidelines have continued to evolve with clinical and therapeutic progress, but androgen-deprivation therapy (ADT) remains the standard of care for non-localised prostate cancer. • Because of the long-term experience (>20 years) and wealth of evidence from the large number of clinical trials, the luteinizing hormone-releasing hormone (LHRH) agonists are currently the main forms of ADT. • Treatment strategies should be adapted to the individual patient in terms of timing, duration and choice of agent. • Prostate cancer remains the most common type of cancer in men and the development of castration-resistant disease seems inevitable, which together drive the clear and continuing need for new, effective agents for ADT to be used alongside the LHRH agonists.
authors.affiliation: Department of Urology, Academic Hospital Braunschweig, Vienna, Austria. p.hammerer@klinikumbraunschweig.de
authors.forename: Peter
authors.initials: P
authors.lastname: Hammerer
authors.forename: Stephan
authors.initials: S
authors.lastname: Madersbacher
mesh_terms: D000069501:Abiraterone Acetate; D000726:Androgen Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000730:Androstadienes / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use*; D001549:Benzamides; D003131:Combined Modality Therapy / Q000379:methods; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D008297:Male; D009281:Naphthalenes / Q000627:therapeutic use; D009570:Nitriles; D010669:Phenylthiohydantoin / Q000031:analogs & derivatives / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists; D000730:Androstadienes; D018931:Antineoplastic Agents, Hormonal; D001549:Benzamides; D007093:Imidazoles; D009281:Naphthalenes; D009570:Nitriles; D010669:Phenylthiohydantoin; C540278:enzalutamide; D000069501:Abiraterone Acetate; C571806:orteronel